EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSLAFG00000015599
Gene Symbol: FLT3
2 External references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSLAFG00000008776
Gene Symbol: FLT4
2 External references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Folate Hydrolase 1

Ensembl ID : ENSLAFG00000010953
Gene Symbol: FOLH1
2 External references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSLAFG00000017106
Gene Symbol: FSHR
2 External references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Free Fatty Acid Receptor 1

Ensembl ID : ENSLAFG00000031093
Gene Symbol: FFAR1
2 External references
138 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Free Fatty Acid Receptor 2

Ensembl ID : ENSLAFG00000005430
Gene Symbol: FFAR2
2 External references
331 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSLAFG00000005589
Gene Symbol: FRK
2 External references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galactosidase Alpha

Ensembl ID : ENSLAFG00000017388
Gene Symbol: GLA
2 External references
196 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galectin 1

Ensembl ID : ENSLAFG00000028162
Gene Symbol: LGALS1
2 External references
380 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Galectin 3

Ensembl ID : ENSLAFG00000005163
Gene Symbol: LGALS3
2 External references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSLAFG00000007512
Gene Symbol: GABRA1
2 External references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSLAFG00000002881
Gene Symbol: GABRA2
2 External references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).